Sign In
Buy AZN
$169.64
-1.70 (-0.99%)
At Close: Jul 31, 2026
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
05:40pm, Sunday, 02'nd Aug 2026
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
04:00pm, Sunday, 02'nd Aug 2026
UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times. The megadeal would be one of the large
AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports
03:36pm, Sunday, 02'nd Aug 2026
UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb , the Financial Times reported on Sunday, citing people familiar with the matter.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
10:00am, Thursday, 30'th Jul 2026
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to co
Amundi Raises Stock Holdings in Astrazeneca Plc $AZN
03:45am, Wednesday, 29'th Jul 2026
Amundi boosted its position in shares of Astrazeneca Plc (NYSE: AZN) by 146,574.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commiss
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
05:27pm, Tuesday, 28'th Jul 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are a
AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales
12:41pm, Tuesday, 28'th Jul 2026
AstraZeneca (AZN), a global pharmaceutical company focused on oncology and other major therapeutic areas, could gain a potential new cancer treatment with estim
AstraZeneca's drug pipeine is splitting opinion among City analysts
09:40am, Tuesday, 28'th Jul 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) drug pipeline is splitting opinion among City brokers, with Citibank upgrading its price target to 17,800p whilst analysts at Deutsche Bank repeated a 'sell'
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript
03:28pm, Monday, 27'th Jul 2026
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
02:57pm, Monday, 27'th Jul 2026
AstraZeneca tops Q2 earnings and revenue estimates as strong demand for oncology and rare disease drugs helps offset growing generic competition across key products.
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
02:16pm, Monday, 27'th Jul 2026
AstraZeneca (AZN), a global pharmaceutical company focused on medicines including cancer and rare-disease treatments, maintained its 2026 and 2030 forecasts aft
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks
12:33pm, Monday, 27'th Jul 2026
AstraZeneca PLC delivered solid Q2 2026 core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year 2026. There could be challenges in store, though, with Farxiga
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:47am, Monday, 27'th Jul 2026
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
10:21am, Monday, 27'th Jul 2026
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 400 points on Monday.
Astrazeneca Q2 Earnings Call Highlights
09:03am, Monday, 27'th Jul 2026
Astrazeneca NYSE: AZN reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per sha
